AstraZeneca
AZN
755 hedge funds and large institutions have $20.4B invested in AstraZeneca in 2021 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 263 increasing their positions, 267 reducing their positions, and 100 closing their positions.
34% more call options, than puts
Call options by funds: $548M | Put options by funds: $409M
4% more capital invested
Capital invested by funds: $19.7B → $20.4B (+$733M)
0.64% more ownership
Funds ownership: 15% → 15.63% (+0.64%)
1% less repeat investments, than reductions
Existing positions increased: 263 | Existing positions reduced: 267
4% less funds holding
Funds holding: 785 → 755 (-30)
22% less first-time investments, than exits
New positions opened: 78 | Existing positions closed: 100
22% less funds holding in top 10
Funds holding in top 10: 18 → 14 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.98B |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$207M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$155M |
| 4 |
Citigroup
New York
|
+$117M |
| 5 |
BlackRock
New York
|
+$87.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$668M |
| 2 |
Jennison Associates
New York
|
-$352M |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$311M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$232M |
| 5 |
D.E. Shaw & Co
New York
|
-$214M |
AZN Hedge Fund Activity: Q1 2021 in Review
755 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2021, worth a combined $20.4B — up 3.7% from $19.7B a quarter earlier.
Sellers outnumbered buyers: 100 funds closed out of AZN and 78 opened new positions — a net loss of 22 holders — while 267 trimmed existing stakes and 263 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $1.98B. The largest seller was Fidelity Investments, cutting an estimated $668M.
- 755 institutional investors held AstraZeneca (AZN) as of Q1 2021, down from 785 in Q4 2020.
- Funds reported $20.4B of AstraZeneca stock for Q1 2021, up 3.7% quarter-over-quarter.
- 78 funds opened new AstraZeneca positions in Q1 2021 and 100 closed out, a net change of -22 holders.
- The largest AstraZeneca buyer in Q1 2021 was T. Rowe Price Associates, an estimated $1.98B added.
- The largest AstraZeneca seller in Q1 2021 was Fidelity Investments, an estimated $668M sold.
Based on aggregated 13F filings for Q1 2021.